Myeloid leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:39 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Myeloid leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Ponatinib for Treating Recurrent or Refractory Leukemias and Solid Tumors in Children https://clinicaltrials.eu/trial/study-on-ponatinib-for-treating-recurrent-or-refractory-leukemias-and-solid-tumors-in-children/ Wed, 29 Apr 2026 14:57:26 +0000 https://clinicaltrials.eu/trial/study-on-ponatinib-for-treating-recurrent-or-refractory-leukemias-and-solid-tumors-in-children/ This clinical trial is focused on studying the effects of a medication called Ponatinib on certain types of cancers in children. The cancers being studied include recurrent or refractory leukemias, which are blood cancers that have returned or do not respond to treatment, and solid tumors, which are abnormal masses of tissue. The purpose of the study is to evaluate the safety and effectiveness of Ponatinib in treating these conditions. Ponatinib is a type of medication known as a kinase inhibitor, which works by blocking certain proteins that help cancer cells grow.

The study is divided into two phases. In the first phase, the goal is to find the best dose of Ponatinib for children with advanced blood cancers or solid tumors. In the second phase, the study will look at how well Ponatinib works in children with a specific type of leukemia called Chronic Myeloid Leukemia (CML) and other selected cancers. Participants will take Ponatinib orally, which means they will swallow it in the form of a tablet or capsule. The study will monitor the participants’ health and any side effects they may experience while taking the medication.

Throughout the study, researchers will assess the participants’ response to the treatment by using various medical tests and imaging techniques like MRI or CT scans. The study aims to provide valuable information on the potential benefits and risks of using Ponatinib in treating these challenging cancers in children. The study is expected to continue until 2025, allowing researchers to gather comprehensive data on the long-term effects of the treatment.

]]> Study Comparing Pevonedistat, Venetoclax, and Azacitidine with Venetoclax and Azacitidine in Adults with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy https://clinicaltrials.eu/trial/study-comparing-pevonedistat-venetoclax-and-azacitidine-with-venetoclax-and-azacitidine-in-adults-with-acute-myeloid-leukemia-unfit-for-intensive-chemotherapy/ Wed, 29 Apr 2026 14:23:16 +0000 https://clinicaltrials.eu/trial/study-comparing-pevonedistat-venetoclax-and-azacitidine-with-venetoclax-and-azacitidine-in-adults-with-acute-myeloid-leukemia-unfit-for-intensive-chemotherapy/ This clinical trial is focused on studying a treatment for Acute Myeloid Leukemia (AML), a type of cancer that affects the blood and bone marrow. The study is comparing two treatment combinations. One group will receive a combination of three medications: Pevonedistat, Venetoclax, and Azacitidine. The other group will receive two medications: Venetoclax and Azacitidine. Pevonedistat is also known by its code name, MLN4924, and Venetoclax is sometimes referred to as ABT-199 or GDC-0199. Azacitidine is a medication used in various forms, including Azacitidine Mylan and Vidaza.

The purpose of this study is to determine if the combination of Pevonedistat, Venetoclax, and Azacitidine is more effective than the combination of Venetoclax and Azacitidine alone in treating adults with newly diagnosed AML who are not suitable for intensive chemotherapy. Participants in the study will be randomly assigned to one of the two treatment groups. The study will monitor the participants over a period of time to assess the effectiveness and safety of the treatments. The study will also look at how long participants live and how their disease responds to the treatment.

Participants will receive their assigned treatment and will be regularly monitored by healthcare professionals. The study will track various outcomes, including how long it takes for the disease to progress, the overall survival of participants, and the response of the leukemia to the treatment. The study aims to provide valuable information that could improve treatment options for patients with AML who cannot undergo intensive chemotherapy.

]]>